An open label, randomized, active controlled, dose finding study to evaluate the pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim at doses of 300 ?g/kg and 670 ?g/kg in pediatric patients diagnosed with solid tumors receiving chemoth
Read time: 1 mins
Last updated:1st Aug 2013
The primary objective of this study is to find the optimal dose of balugrastim by characterizing its pharmacokinetics (PK), and by comparing the pharmacodynamics (PD) of balugrastim to filgrastim during Cycle 1 in children receiving chemotherapy.
|Study start date||2013-08-01|